This activity already occurred and is no longer available.
Concise Clinical Review: Adverse Bone Effects of Medications Used to Treat Non-skeletal Disorders
Bone loss and increased fracture risk caused by therapies for non-skeletal diseases is a growing and important cause of osteoporosis.

Initial Date: October 1, 2017

Expiration Date: September 30, 2019 

Credits Available: 1.0 hour

Fee: Member-$0; Nonmember-$0

Faculty Disclosures:

Dr. Nelson Watts: OsteoDynamics, co-founder, stockholder; Honoraria for lectures the past year: Amgen, Merck, Shire; Consulting fees: AbbVie, Amgen, Janssen, Merck, Radius, Sanofi.

Activity Description

There is a growing list of medications used to treat non-skeletal disorders that cause bone loss and/or increase fracture risk. This review discusses glucocorticoids, drugs that reduce sex steroids, antidiabetic agents, acid-reducing drugs, selective serotonin reuptake inhibitors, and heparin. A number of drugs are known to cause bone loss, increase fracture risk, or both.

Target Audience

This continuing education activity is intended for use by health professionals who participate in the care of patients at risk for or suffering from osteoporosis, in the areas of primary care, endocrinology, geriatrics, gynecology, internal medicine, obstetrics, orthopedics, osteopathy, pediatrics, physiatry, radiology, rheumatology and physical therapy.

This includes physicians, nurse practitioners, registered nurses, pharmacists, physician assistants, technologists, researchers, public health professionals and health educators with an interest in osteoporosis and bone health.

Learning objectives:

On completion of this article, you should be able to recognize the following:
  1. Describe some of the medications that may contribute to bone loss and/or fracture risk.
  2. Identify mechanisms by which these effects occur.
  3. Explain potential counter-measures for managing effects.


The National Osteoporosis Foundation is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The National Osteoporosis Foundation designates this educational activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)
TM. Physicians should only claim credit commensurate with the extent of their participation in the activity.

CME Program Eligibility

Method of Participation in the Learning Process: Clinician learners will read and analyze the subject matter, conduct additional informal research through related internet searches on the subject matter, and complete a post-test assessment of knowledge and skills gained as a result of the activity.

After participating in this activity, the reader has the option of taking a post-test with a passing grade of 70% or better to qualify for continuing education credit for this activity. It is estimated it will take 1.0 hour(s) to complete the reading and take the post-test. Continuing education credit will be available for two years from the date of publication.

Disclosure of Commercial Support

It is the policy of the National Osteoporosis Foundation (NOF) to ensure balance, independence, objectivity, and scientific rigor in all its sponsored publications and programs. NOF requires the disclosure of the existence of any significant financial interest or any other relationship the sponsor, Editorial Board or Guest Contributors have with the manufacturer(s) of any commercial product(s) discussed in an educational presentation. All authors and contributors to this continuing education activity have disclosed any real or apparent interest that may have direct bearing on the subject matter of this program.

Please be advised that NOF’s accreditation status with ACCME does not imply endorsement by NOF or ACCME of any commercial products displayed in conjunction with this activity or endorsement of any point of view.

Statement regarding OFF Label Use

Please be advised that any publication of the Osteoporosis Clinical Updates that discusses off-label use of any medications or devices will be disclosed to the participant.

Refund Policy

NOF offers no returns or refunds on online internet CME activities purchased through our store. All sales are final. Meeting and workshop registrations will be refunded in accordance with the cancellation policy of the meeting and/or workshop, as outlined at registration.

Type:     Internet Activity (Enduring Material)
93 Registered Users

National Osteoporosis Foundation

251 18th Street South, Suite 630, Arlington, VA 22202 I [p] 1 (800) 231-4222 • [f] 1 (703) 414-3742

The National Osteoporosis Foundation is a qualified 501(c)(3) tax-exempt organization and all donations to the organization are
tax deductible to the full extent allowable by law. NOF’s tax ID number is 36-3350532.